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Erectile dysfunctionThe metabolic syndrome (MetS) is an insulin-resistant state characterized by a cluster of cardiovascular risk
factors, including abdominal obesity, hyperglycemia, elevated blood pressure and combined dyslipidemia. In
this review, we discuss the potential of farnesoid X receptor (FXR) agonists in the treatment of erectile
dysfunction (ED), a multifactorial disorder often comorbid withMetS. FXR not only regulates lipid and glucose
homeostasis but also inﬂuences endothelial function and atherosclerosis, suggesting a regulatory role for this
hormone nuclear receptor in the cardiovascular complications associated with the MetS, including ED. MetS
induces ED via several mechanisms, and in particular through endothelial dysfunction in penile vessels. In a
high-fat diet rabbit model of MetS, a 3-month treatment with the potent and selective FXR agonist INT-747
restores endothelium-dependent relaxation in isolated cavernous tissue, normalizing responsiveness to
acetylcholine and to electrical ﬁeld stimulation. Accordingly, eNOS expression in the penis is greatly up-
regulated by INT-747 treatment. Experiments in a rat model of chemically-induced type 1 diabetes further
demonstrate that INT-747 treatment preserves erectile function induced by electrical stimulation of the
cavernous nerve. These results add a new facet to the pleiotropic activities mediated by FXR, and reveal novel
beneﬁcial effects of FXR activation with potential clinical relevance. This article is part of a Special Issue
entitled: Translating nuclear receptors from health to disease.slating nuclear receptors from
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Erectile dysfunction (ED) is deﬁned as the consistent inability to
achieve and/or maintain an erection sufﬁcient for satisfactory
intercourse [1]. ED is a very common multidimensional disorder
that has detrimental effects on sexual and reproductive activity,
thereby impairing the quality of life of both the patient and his
partner. A 2009 analysis of all population-based studies conducted in
the US indicates that ED is indeed the most common endocrine
disorder in men [2]. A European survey showed that ED affects almost
30% of men in an age-dependent manner [3]. ED results from a
continuous spectrum of clinical factors, including physical illness (the
organic component of ED), reaction to stress (the intrapsychic
component of ED) and relationship difﬁculties (the relationship
component of ED), which are often simultaneously present in ED
patients and mutually concur in determining the disorder [4,5].
However, the most important risk factors for ED are associated to the
impaired balance between contractant and relaxant mechanisms ofpenile structures, resulting in arterial insufﬁciency and defective
smooth muscle relaxation.
Thus, penile erection is essentially a neurovascular event initiated
by sexual arousal, which stimulates release of nitric oxide (NO) at
nerve endings in the penis resulting in the engorgement of the two
sponge-like cavernous bodies (corpora cavernosa) with blood (Fig. 1).
The NO produced through NO synthase, present in both endothelial
cells and neurons, diffuses into smooth muscle cells (SMCs) and
increases the formation of cyclic GMP (cGMP), which, through cGMP-
dependent protein kinase G, promotes SMC relaxation by decreasing
intracellular calcium levels. Relaxation of cavernous SMCs increases
blood ﬂow to cavernosal sinuses and mediates venous occlusion,
resulting in penile engorgement and rigidity. The formation of cGMP
is actively counteracted by a series of phosphodiesterases (PDEs), the
most important of which is PDE5 [6]. In human corpora cavernosa,
PDE5 alone accounts for the breakdown of the majority (~70%) of
cGMP [7]. Conversely, sympathetic nerve activity is mainly respon-
sible for maintaining SMCs in a contractile state. When released from
nerve endings, norepinephrine binds to its cognate receptors.
Receptor binding activates two separate pathways within the cells,
one leading to the activation of rho kinase (ROCK) and the other
causing increased levels of inositol triphosphate, which result in
increased intracellular calcium levels and calcium sensitization. As
soon as pro-contractile transmitters, as endothelin-1 (ET-1) or
Fig. 1. FXR-mediated molecular mechanism underlying modulation of corpora cavernosa smoothmuscle cell function. Following FXR activation by INT-747, induction of eNOS, nNOS
and DDAH1 positively regulates NO release from endothelium and nerves leading to NO/cGMP-mediated smooth muscle cell relaxation. The inhibition of the pro-contractile RhoA/
ROCK signaling by FXR activation further promotes corpora cavernosa smooth muscle cell relaxation and thereby erectile function. NANC, nonadrenergic noncholinergic; NO, nitric
oxide; eNOS, endothelial NO synthase; nNOS, neuronal NOS; DDAH1, dimethylarginine dimethyl-aminohidrolase-1; sGC, soluble guanylate cyclase; GTP, guanosine triphosphate;
GMP, guanosinemonophosphate; cGMP, cyclic GMP; PKG, cGMP-dependent protein kinase; PDE5, phosphodiesterase type 5;MLC,myosin light chain;MLCK,MLC kinase;MLCP,MLC
phosphatase; MYPT1, myosin phosphatase target subunit 1; ATP, adenosine triphosphate; ROCK, Rho-kinase; CPI-17, protein-kinase C-potentiated myosin phosphatase inhibitor.
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monomeric GTPase proteinmainly localized in the cytosol in its RhoA-
guanosine diphosphate (GDP) inactive form, exchange in an active
guanosine triphosphate (GTP)-bound complex that translocates to
the plasma membrane. Upon activation, RhoA-GTP anchors to the
membrane through its geranylgeranyl pyrophosphate (GGPP) iso-
prenoid group and activates its downstream effectors, among which
ROCK is the best characterized. The two described ROCK isoforms
(ROCK1 or ROKb, and ROCK2 or ROKa) are serine-threonine kinases
that are able to maintain the phosphorylated state of the myosin
light chain (MLC) by phosphorylating and inhibiting the myosin
phosphatase target subunit 1 (MYPT1) of MLC phosphatase, thereby
promoting actin/myosin cross-bridging and contraction, indepen-
dently of intracellular calcium levels [8,9]. Finally, RhoA/ROCK
pathway plays a major role in maintaining the contractile tone in
penile SMC, independently of intracellular calcium levels [5,8–11].
As brieﬂy reviewed above, ED is a multifactorial disorder.
However, organic factors are found in more than 80% of cases and
include endocrine, neurogenic and arteriogenic causes [5,12,13]. In
particular, endothelial dysfunction has been reported as the most
important determinant of ED, and ED itself is now recognized as one of
the earliest manifestations of a forthcoming cardiovascular disease
(CVD) [14]. The “artery size hypothesis” indicates that ED, on average,
occurs 3 years earlier than a subsequent CVD, because the smaller
penile arteries reach critical narrowing, with insufﬁcient blood ﬂow,
earlier than larger vessels [15,16]. Accordingly, the Prostate Cancer
Prevention Trial reported that incident ED was associated with a
hazard ratio of 1.25 [1.02–1.69] for subsequent cardiovascular events,
during 9 years follow up after adjustment for confounders [17].
Hence, detecting an arteriogenic ED might help clinicians in prevent-
ing further CVD complications.In most cases, the ﬁrst-line pharmacological approach for ED is
based on phosphodiesterase type 5 (PDE5) inhibitors, competitive
inhibitors of cGMP for PDE5 [18]. Three oral PDE5 inhibitors are
currently available: sildenaﬁl, vardenaﬁl, and tadalaﬁl, whilst a
number of newer agents are licensed in a few countries (udenaﬁl,
mirodenaﬁl) and others (avanaﬁl, lodenaﬁl, SLX-2101) are currently
under development. The efﬁcacy, safety, and tolerability of PDE5
inhibitors have been recently reviewed [19]. However, a large number
of men are unable to utilize oral treatments for ED. This is mainly due
to the fact that 25–32% of ED-patients are non-responders to PDE5
inhibitors and some have contraindications to PDE5 inhibitors. These
patients are shifted to second-line treatments, local and invasive
therapy with vasoactive agents. Three main vasoactive drugs are
currently used for intracavernosal injection (ICI) therapy of ED,
namely prostaglandin E1 (PGE1), vasoactive intestinal polypeptide
and phentolamine [19]. Most commonly reported adverse effects are
penile pain, occurring in 50% of patients, and prolonged erections.
Table 1 summarizes the main pharmacological therapies for ED
currently used or under development.
2. Metabolic syndrome
Metabolic syndrome (MetS) is a diagnostic category, based on a
cluster of risk factors (hyperglycemia/diabetes, abdominal obesity,
hypertriglyceridemia, low HDL cholesterol and hypertension), which
identiﬁes subjects at high risk for forthcoming type 2 diabetes mellitus
(T2DM) and CVD [20,21]. Any deﬁnition of MetS is, at present, largely
arbitrary. In epidemiological studies, theNational Cholesterol Education
Program-Third Adult Treatment Panel criteria (NCEP-ATPIII) [22] are
used frequently due to their simplicity, rather than to an intrinsic
superiority [20]. MetS, according to the NCEP-ATPIII deﬁnition, is the
Table 1
Characteristics of pharmacological therapies for ED currently used or under development.
Sildenaﬁl Vardenaﬁl Tadalaﬁl Udenaﬁl SLx-2101 Avanaﬁl Mirodenaﬁl Lodenaﬁl
PDE5 inhibitors
Formulation
(mg)
25, 50, 100 5, 10, 20 10, 20 100, 200 5, 10, 20, 40, 80 50, 100, 200, 300 50, 100 20, 40, 80
Pharmacokinetic properties
Tmax, (h) 1 1 2 1–1.5 1 0.33–0.52 1.25 1.2
Cmax, ng/ml
(fasting)
450
(100 mg)
20.9
(20 mg)
378
(20 mg)
416
(100 mg)
No data 3992
(200 mg)
No data 157
(160 mg)
T1/2 (h) 3–5 4 17.5 11–13 9–14 5.3–10.6 2.5 2.4
Advantages Oral Oral Oral, longer
duration of action
Oral, longer
duration of action,
greater selectivity
Oral, fast-onset,
long-acting
Oral, fast-onset,
short duration
of action
Oral, effective and
safe in men with ED
concomitantly
taking
antihypertensive
medications
Oral
Side effects Headache, ﬂushing,
dyspepsia, occasional
visual changes, nasal
congestion, rare
cardiovascular risks
Nausea, ﬂushing,
dyspepsia, nasal
congestion, rare
heart attack risk
Headache, ﬂushing,
dyspepsia, nasal
congestion, back or
girdle pain, priapism
Facial ﬂushing,
nasal congestion,
ocular hyperemia,
headache
No data Flushing, headache,
dizziness, nasal
congestion,
orbital pain
Facial ﬂushing,
headache,
nausea,
eye hyperemia
Headache,
dyspepsia,
rhinitis,
ﬂushing,
color visual
disorders
References [19,90] [19,90] [19,90] [19,91] [19] [19,92] [19,93,94] [19,95]
Intracavernosal prostaglandin E1
Formulation 10 μg
Advantages Low cost
Side effects Penile pain; prolonged erection
References [19,96]
Intraurethral prostaglandin E1
Formulation 0.5, 1 mg
Side effects Urethral pain
References [19,97]
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(waist circumference N102 cm), elevated triglycerides (≥1.7 mmol/l or
150 mg/dl), elevated blood pressure (BP≥130/85 mm Hg), elevated
fasting glucose (≥6.1 mmol/l or 110 mg/dl) and reduced HDL choles-
terol (b1.03 mmol/l 40 mg/dl) [22]. Moreover, all individuals receiving
pharmacological treatment for hypertension, hypertriglyceridemia or
lowHDL cholesterol, and all individuals previously diagnosedwith type
2 diabetes, should be considered aspotentially afﬂictedbyMetS. Besides
the NCEP-ATPIII criteria, other deﬁnitions exist, and a most recent one
from the International Diabetes Federation designates central obesity as
an essential requirement [23]. Independent of its deﬁnition, MetS has
been associated with a two-fold increase of 5- to 10-year risk of CVD,
and a ﬁve-fold increase in risk for T2DM [21]. Despite this evidence, the
clinical use of this category, and in particular its utility as a predictor of
CVD, has been the subject of vigorous debate [24–29]. Given that
individualMetS components are all cardiovascular risk factors, it is quite
obvious that subjects with MetS have elevated CV risk. The hypothesis
underlying the use of MetS in predicting CVD is based on the concept
that its components could somehowhave a synergistic effect on CV risk.
Thus, the overall risk conferred byMetS should be greater than the sum
of the risks associated with each of its individual components [30–32].
The evidence available, however, does not support this hypothesis. In a
case-control study involving 393 early-onset coronary artery disease
subjects, the prognostic information associated with the syndromewas
not greater than the sum of its parts [33]. More recently, similar results
were also reported in the INTERHEART study, a case-control study
on the incidence of acute myocardial infarction involving more than
26,000 subjects in 52 countries [34] as well as in the RIVANA study, a
population-based study involving 880 individuals [35]. In addition, the
Rancho Bernardo Study, a community-dwelling sample of 338 partici-
pants with an average age of 67 years did not report any association
betweenMetS andCVD [36]. In linewith these results, a recent reviewof
3459 patients who participated in 7 clinical trials monitoring coronaryatheroma progression with intravascular ultrasonography demonstrat-
ed that, although accelerated disease progression was observed in the
presence of MetS, this was due to the presence of individual component
risks rather than to the presence of the syndrome itself [37].
3. Erectile dysfunction and metabolic syndrome
A large bodyof evidence suggests thatMetS is frequently associated
with ED and unresponsiveness to PDE5 inhibitors [5,20,38–40]. The
prevalence of ED in subjects with MetS ranges from 27% [41] to 80%
[42] and it is strictly associated with the number of MetS components
and with the endothelial function impairment [5,20,38–40]. Longitu-
dinal data indicate that ED can even be a predictor ofMetS inmenwith
normal weight at baseline [43]. Hence, ED could be the ﬁrst sign of
MetS and one of the earliest manifestations of a forthcoming CVD
[32,44]. Accordingly, we have recently reported results from an
observational prospective cohort study, involving a consecutive series
of almost 1700 ED subjects, with an 8-year follow-up in which we
showed that severe ED and reduced penile blood ﬂow almost double
the risk of incident major cardiovascular diseases, even after adjusting
for age and comorbidities [45]. ED, previously considerednomore than
a frustrating condition, should thus be regarded as a good opportunity
to screen for the presence of ED-associated comorbidities, such as
MetS and silent CVD.
The association amongMetS, ED, and hypogonadism has been also
well recognized and the presence of hypogonadism in men with MetS
and ED is associated with a greater severity of symptoms of sexual
dysfunctions, other than ED [5]. The speciﬁc mechanisms underlying
these associations are not completely clariﬁed, although insulin
resistance has been recently considered the common pathogenetic
link between ED, MetS and male hypogonadism [46]. Accordingly, in
insulin-resistant individuals, such as thosewithMetS, insulin-induced
production of nitric oxide is impaired [47]. Furthermore, insulin-
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produce lesions on penile arteries, therefore inducing a reduction of
penile blood ﬂow. Consistent with these ﬁndings, we have previously
demonstrated that HFD-induced MetS [48] and streptozotocin-
induced diabetes in animal models [49,50] are associated with penile
function impairment.
Several neurotransmitters and endothelial factors have been
shown to control erectile function by modulating the penile
vasculature and smooth muscle tone of corpora cavernosa. Among
these factors, NO released by nerves and endothelium in the penis
plays a crucial role in the initiation and maintenance of increased
intracavernous pressure and penile erection, but the normal erectile
function is warranted by a tight balance between relaxant and
contractile factors. Pathological conditions that alter this balance, such
as those associated with reduced function of nerves and endothelium
and/or overactivity of RhoA/ROCK contractile signalling in the penis
(i.e. aging, hypertension, smoking, diabetes and MetS), cause
changing in penile tissue function resulting in impaired smooth
muscle relaxation and erection [50–53]. In human penile cells,
hyperglycemia per se promotes activation of RhoA/ROCK pathway
[53]. Conversely, nitric oxide synthase (NOS) activity is decreased by
MetS [48] and type 1 diabetes [50,53–56], which also increases penile
ﬁbrosis by altering the smooth muscle/ﬁber ratio [50,57].
4. Signaling via farnesoid X receptor regulates glucose and lipid
metabolism, with protective effects on the vasculature
The farnesoid X receptor (FXR) is a nuclear receptor functioning as
an endogenous sensor for bile acids [58]. FXR is expressed at high
levels in liver, intestine, kidney and at lower levels in adipose tissues,
and is most potently activated by the primary bile acid chenodeoxy-
cholic acid [58]. Besides expression in hepatocytes and enterocytes
[58], FXR immunolabeling was observed in glandular cells in the zona
reticularis/fasciculate of the adrenal gland and in the tubular
epithelial cells of proximal, distal and collecting tubules of the kidney
[59]. FXR is also expressed in preadipocytes and mature adipocytes of
white adipose tissue [60], in pancreatic β-cells [61], in different cells
of the immune system [58], and in smooth muscle and endothelial
cells of the vascular bed [62].
Activation of FXR is involved in maintaining not only bile acid
homeostasis, but also in regulating the intricate network governing
lipid, cholesterol, and energy homeostasis, transport andmetabolism of
fatty acids and triglycerides, and control of glucose homeostasis [58].
FXR activation can also regulate immune responses, exerting an
overall anti-inﬂammatory effect [58]. FXR agonists have been shown
to suppress hepatic fatty acid and triglyceride synthesis through down-
regulation of SREBP1c, and increase hepatic fatty acid oxidation through
up-regulation of pyruvate dehydrogenase kinase 4 (PDK4) [58]. In
agreement with these ﬁndings, plasma cholesterol and triglyceride
levels are increased in FXR-deﬁcient mice [63], which also show
impaired glucose tolerance and insulin resistance [60]. In addition, loss
of FXR function is associatedwith decreased survival, increased severity
of defects in lipid metabolism, and more extensive aortic plaque
formation in a mouse model of atherosclerotic disease [64].
Based on its important role in multiple metabolic pathways;
accumulating evidence indicates that FXR may represent a promising
pharmaceutical target for the treatment of deﬁned metabolic diseases
[65,66]. In particular, considering its capacity to regulate lipid and glucose
metabolism as well as the atherosclerosis process with direct actions on
the arterial wall, FXR modulation may be instrumental in the global
management of cardiovascular risk factors associated with theMetS [67].
4.1. INT-747, a potent and selective FXR agonist
The semi-synthetic chenodeoxycholic acid derivative 6α-ethyl
chenodeoxycholic acid (INT-747, obeticholic acid) is a selective andpotent FXR agonist originally described for its anti-cholestatic
properties [68]. Biodistribution and mass balance studies have
demonstrated that INT-747 is well absorbed and efﬁciently conserved
in the enterohepatic circulation. A small proportion of the parent
compound is found in plasma, where it is mainly present as glyco- or
tauro-conjugate, depending on the species examined, and quantita-
tion of INT-747 as well as its metabolites in rabbit serum and corpora
cavernosa is ongoing. INT-747 has been shown to have profound
regulatory effects on lipid and glucose metabolism [69]. INT-747
improves glycemia by increasing peripheral glucose uptake, enhanc-
ing glucose-stimulated insulin secretion, and inhibiting hepatic lipid
synthesis and content while inducing lipid uptake by adipocytes
[70,71]. INT-747 has been successfully tested in phase II clinical
studies in patients with primary biliary cirrhosis, as well as in patients
with T2D and non-alcoholic fatty liver disease [69].
Moreover, a potential new role for FXR in the pathogenesis of
cardiovascular disease has been proposed, also via a direct action on
the vasculature. FXR activation by INT-747 in smooth muscle and
endothelial cells of the vascular bed leads to apoptosis and inhibition
of vascular inﬂammation, with beneﬁcial effects potentially prevent-
ing cell adhesion and thrombosis [72]. Notably, INT-747 down-
regulates IL-1β-induced iNOS and cyclooxygenase-2 expression, and
inhibits IL-1β-induced NF-κB activation and iNOS expression, show-
ing important anti-inﬂammatory effects in vascular cells [72].
Preclinical studies using FXR and ApoE double-knockout mice fed a
high-cholesterol diet show increased tendency towards development
of atherosclerotic lesions in comparison with single-knockout mice,
suggesting that FXR activation might have a mechanistic implication
in protecting against atherosclerosis. In ApoE–/– mice administration
of INT-747 reduces the formation of aortic plaque area by 95%, with a
similar anti-plaque activity to rosiglitazone [73]. INT-747 treatment
inhibits diet-induced renal lipid accumulation, inﬂammation, ﬁbrosis,
and proteinuria [74]. In addition, INT-747 prevents the development
of type 1 diabetic nephropathy by decreasing proteinuria, glomerulo-
sclerosis and tubulointerstitial ﬁbrosis and modulating renal lipid
metabolism, macrophage inﬁltration and renal expression of SREBPs,
proﬁbrotic growth factors and oxidative stress enzymes [75]. INT-747
inhibits also phosphate-induced mineralization and triglyceride
accumulation in calcifying vascular cells and ameliorates chronic
kidney disease-induced vascular calciﬁcation in 5/6 nephrectomized
ApoE−/−mice [76]. Overall, these ﬁndings suggest that FXR activation
by potent and selective FXR agonists like INT-747 may open new
attractive pharmacological approaches for the treatments of MetS-
related vascular dysfunction, including ED.
5. FXR activation by the selective agonist INT-747 improves ED in
animal models of metabolic syndrome and diabetes
As reviewed above, growing evidence indicates that FXR regulates
vascular homeostasis and remodelling [62], suggesting its potential
role in the cardiovascular complications associated with the MetS
[67]. Expression of FXR has been detected in both endothelial cells and
smooth muscle cells involved in atherosclerotic plaque formation
[58]. FXR-mediated regulation of endothelial NOS (eNOS) expression
has been demonstrated in vascular endothelial cells [77], thus
suggesting the involvement of this intracellular signalling in the
positive regulation of vascular endothelial function. FXR might also
interfere with endothelium-derived NO activity through modulation
of serum asymmetric dimethylarginine (ADMA). ADMA is an
endogenous NOS inhibitor and elevated plasma ADMA levels are
associated with reduced NO synthesis in diseases related to
endothelial dysfunction, including hypertension, hyperlipidemia,
and diabetes mellitus [78,79]. In vitro studies have shown that FXR
activation reduces ADMA formation by positively regulating the
expression/activity of hepatic dimethylarginine dimethyl-aminohy-
drolase-1 (DDAH1), the major catabolic pathway of ADMA [80].
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activation induces kininogen mRNA [81], which might result in
increased local bradykinin in corpora cavernosa tissue thus resulting
in vasodilation through the bradykinin receptor B2 signaling.
Moreover, downregulation of ET-1 (with vasoconstrictive activity)
in penile tissue could also contribute to the vasodilatory effect of FXR
activation [82].
We have recently investigated the role of FXR activation on erectile
function in two animal models of metabolic derangements: a rabbit
model of high-fat diet (HFD)-induced MetS and a rat model of
streptozotocin (STZ)-induced type 1 diabetes [83]. Both models are
characterized by penile alterations [48,84]. FXR is expressed in penile
tissue from different species, including humans, rats and rabbits, in
both endothelial and smooth muscle cells of the vascular bed and
cavernous spaces (Fig. 2). In addition, penile FXR expression is clearly
up-regulated by chronic INT-747 treatment in both rabbit and rat
models, thus suggesting not only that erectile tissue may be a target
for FXR agonists, but also the existence of a positive feedback loop.
Since chronic activation of FXR by non-steroidal FXR agonists (e.g. in
mouse liver cells/tissue) does not necessarily result in upregulation of
FXR mRNA, the effect observed in rabbit penile tissue after chronic
INT-747 application appears novel and requires future investigations
for clarifying whether other classical target tissues for INT-747, such
as liver, show increased FXR expression.Fig. 2. Immunolocalization of FXR in human and rabbit corpora cavernosa (CC). Transverse sec
(arrows) and endothelial cells (arrowheads) of the vascular bed and cavernous spaces (magn
(panel D, magniﬁcation ×20) and HFD plus INT-747-treated rabbits (panels E and F, magniﬁc
(arrows) and endothelial cells (arrowheads) of the vascular bed and cavernous spaces of ra
Adapted from Ref. 68 with permission.In HFD rabbits, NO-mediated relaxation of isolated penile strips is
hampered, as demonstrated by the blunted responsiveness to both
acethylcoline and non-adrenergic non-cholinergic (NANC) nerve
stimulation [48]. Accordingly, eNOS expression, along with DDAH1,
was impaired in penile tissue from HFD rabbits. Chronic administra-
tion with INT-747 in HFD rabbits was able to partially restore penile
responsiveness to both acetylcholine and NANC stimulation, and to
increase both eNOS and DDAH1 expression in penile tissue [83]. This
ﬁnding is consistent with the previously reported capacity of FXR
triggering to directly enhance transcriptional activation of eNOS gene
promoter in vascular endothelial cells [77] and of DDAH1 in the liver
[80]. The expression of FXR in human and rabbit penile endothelial
vascular cells, along with the almost complete normalization of the
response to Ach and NANC stimulation, is consistent with an INT-747-
mediated up-regulation of NO formation in corpora cavernosa.
Interestingly, FXR activation in penile tissue appears to be linked
not only to the NO-mediated relaxation but also to the modulation of
the pro-contractile RhoA/ROCK signaling. The relaxation induced by
the NO-donor sodium nitroprusside (SNP), which bypasses NO
formation, was more pronounced in HFD rabbits than in controls,
and even more pronounced in INT-747-treated HFD rabbits. A
possible explanation for this ﬁnding is that cGMP breackdown by
PDE5 is reduced in HFD rabbits and not restored by INT-747, because
of a MetS-induced down-regulation in PDE5 expression [48].tions of human CC (panels A and B). FXR immunopositivity is localized in smoothmuscle
iﬁcation ×20). Transverse sections of CC from control (panel C, magniﬁcation ×20), HFD
ation ×20 and ×40, respectively). FXR-immunopositivity is localized in smooth muscle
bbit CC.
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responsiveness of penile strips to SNP was not further increased by
blocking PDE5 with selective inhibitors, due to the reduced abun-
dance of their target enzyme. However, the down-regulation of PDE5
did not fully explain the more pronounced relaxant effect of SNP in
INT-747-treated rabbits, suggesting that FXR activation could target
additional mechanisms, likely interfering with RhoA/ROCK signaling.
Indeed, this pathway is hyperactive in corpora cavernosa of diabetic
animal models and its inhibition causes penile smooth muscle
relaxation, normalizing erectile function [50,53,85]. Studies in
human fetal penile smooth muscle cells have demonstrated that
high glucose (40 mM) is able to increase the membrane expression of
active RhoA and MYPT-1 phosphorylation, indicating ROCK activity
[53]. RhoA membrane fraction is signiﬁcantly increased in penile
tissue fromHFD rabbits. This increase is prevented by in vivo, and even
in vitro (in isolated penile smooth muscle cells) treatment with INT-
747, which determines RhoA accumulation in the cytosol, therefore
decreasing ROCK activity [83]. Accordingly, ET-1-stimulated MYPT-1
phosphorylation is decreased in penile cells by INT-747. Cellular
events downstream RhoA/ROCK activation, such as cytoskeleton
remodelling, expression of a motile phenotype, cell migration and
expression of SM22 and αSMA are all down-regulated by in vitro
exposure to INT-747 [83].
The beneﬁcial effects of INT-747 in HFD-induced MetS were
associated not only with up-regulation of NO transmission and
inhibition of RhoA/ROCK pathway in penile tissue, but also with
normalization of visceral adiposity and glucose intolerance [83].
Hence, in this animal model the efﬁcacy of FXR activation on erectile
function could be secondary to its metabolic effects. To rule out this
possibility, a direct effect of INT-747 on erectile function has been
tested in the rat model of STZ-induced type 1 diabetes, characterized
by a marked hyperglycemia, in order to clarify whether INT-747 could
improve erectile function independently of the effect on glycemia.
In this rat model, type 1 diabetes is associatedwith hyperactivity of
RhoA/ROCK pathway, as demonstrated by the higher intracavernous
pressure increase in response to intracavernous injection of the ROCK
inhibitor Y-27632, in comparison to age-matched controls [50,53].
INT-747 dosing for 8 weeks completely restored penile responsive-
ness to Y-27632 in diabetic rats, suggesting in vivo down-regulation of
the hyperactive RhoA/ROCK pathway. In addition, INT-747 completely
normalized the depressed response of STZ-treated rats to electrical
stimulation of the cavernous nerve. Interestingly, several of the STZ-
induced metabolic alterations, such as hyperglycemia, hypercholes-
terolemia and hypogonadism, were not normalized by INT-747 dosing
into diabetic rats [83]. These ﬁndings suggest that INT-747 may
improve in vivo penile erection affected by diabetes independently of
the effects of this FXR agonist on glycemic control. However,
additional mechanistic investigations are required to clarify the role
of FXR signaling in erectile function.
INT-747 shows a modest agonistic activity for the G protein-
coupled receptor TGR5 [86,87], increasing intracellular cAMP with an
EC50 of 20 μM [71]. An increase in intracellular cAMP levels could lead
to corpora smooth muscle relaxation and penile erection [88],
therefore future studies are required to clarify a possible TGR5-
mediated action of INT-747 in penile tissue. However, bile acid-
induced vasorelaxation was not dependent upon stimulation of a bile
acid surfacemembrane receptor, suggesting lack of TGR5 involvement
[89]. In addition, the induction of eNOS and DDAH genes, both
containing FXR responsive elements in their promoter region, by INT-
747 [83] may indicate a prominent role of FXR activation in the INT-
747-induced effects on erectile function.
6. Concluding remarks
Activation of FXR is involved in maintaining not only bile acid
homeostasis, but also in regulating the intricate network governinglipid and glucose homeostasis, highlighting potential beneﬁcial effects
in the treatment of MetS, a condition frequently associated with ED.
The data reviewed here demonstrate that ED associated to metabolic
derangements may be improved by FXR activation through molecular
mechanisms which, although not yet fully elucidated, appear to be
able to interfere with the RhoA/ROCK signaling and restore NO-
mediated relaxation. FXR activation by chronic dosing with the
selective FXR agonist 6α-ethyl chenodeoxycholic acid (INT-747)
improves erectile function in two different animal models of
metabolic derangement by decreasing RhoA/ROCK signaling and
restoring sensitivity to Ach and NANC stimulation. These results
extend to the corpora cavernosa the protective activities mediated by
FXR on the vasculature, revealing novel beneﬁcial effects of INT-747
with potential clinical relevance. ED is now considered one of the ﬁrst
manifestations of MetS and a sentinel of forthcoming cardiovascular
and metabolic events. FXR agonists, with the capacity to improve not
only the metabolic proﬁle but also erectile function, may offer to ED
subjects with underlying conditions such as MetS, the chance to
restore not only sexual but, most importantly, overall health.References
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